Back to top
more

Sanofi (SNY)

(Delayed Data from NSDQ)

$51.26 USD

51.26
3,013,431

-1.59 (-3.01%)

Updated Nov 6, 2024 03:59 PM ET

After-Market: $51.26 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (59 out of 251)

Industry: Large Cap Pharmaceuticals

Zacks News

Regeneron in Strategic Immuno-Oncology Collaboration With ISA

Regeneron Pharmaceuticals (REGN) and ISA Pharmaceuticals inked an agreement to advance ISA101 in combination with cemiplimab.

    Alnylam/Sanofi Submit MAA in Europe for RNAi Candidate

    Alnylam (ALNY) and partner Sanofi have submitted a Marketing Authorization Application to the European Medicines Agency for patisiran for the treatment adults with hereditary ATTR amyloidosis with polyneuropathy.

      Novo Nordisk's (NVO) Semaglutide Gets Positive CHMP Opinion

      Novo Nordisk (NVO) announced that the Committee for Medicinal Products for Human Use has adopted a positive opinion recommending marketing authorisation of semaglutide for the treatment of adults with type II diabetes mellitus.

        Sanofi/Alnylam Say FDA Lifts Clinical Hold on Fitusiran

        Sanofi (SNY) and Alnylam announced that the FDA has lifted the clinical hold placed on all ongoing studies of its hemophilia candidate, fitusiran.

          Mylan Announces IPR Proceedings for Sanofi's Lantus Patents

          Mylan (MYL) announced that interpartes review (IPR) proceedings has been initiated by PTAB regarding two Orange Book-listed patents, U.S. Patent Nos. 7,476,652 and 7,713,930 owned by Sanofi.

            Cancer Space Update: Roche, Pfizer & Regeneron Make Data Presentations

            Several presentations at the annual meeting of the American Society of Hematology grab headlines in the cancer space.

              Arpita Dutt headshot

              Pharma Stock Roundup: Teva Announces Major Job Cuts, Lilly Provides 2018 Outlook

              This week's pharma sector highlights include ASH data, Teva's restructuring announcement and Lilly's (LLY) 2018 outlook.

                Lilly Issues Guidance for 2018, New Drugs to Drive Top Line

                Eli Lilly (LLY) issues financial guidance for 2018 and also reaffirms the previously issued 2017 projection as well as its long-term expectations.

                  Regeneron, Sanofi Report Positive Top Line Skin Cancer Data

                  Regeneron (REGN) and partner Sanofi announced positive top-line results from a pivotal phase II study of skin cancer candidate cemiplimab.

                    Intersect ENT (XENT) SINUVA Implant Receives FDA Approval

                    Intersect ENT's (XENT) consistent focus on the chronic sinusitis market is likely to lend the company a competitive edge in the niche space.

                      Sanofi Wins FDA Approval for Biosimilar of Lilly's Humalog

                      Sanofi's (SNY) Admelog, a follow-on biologic version of Lilly's Humalog, received FDA approval.

                        Arpita Dutt headshot

                        3 Stocks in Focus as Biotech M&A Hopes for 2018 Rise

                        With tax reform on the horizon, the biotech sector is expected to witness a surge in M&A deals. Here is a look at Juno (JUNO) and two other biotech stocks that could be on the acquisition radar.

                          Sanofi Begins Combo Studies on Multiple Myeloma Candidate

                          Sanofi (SNY) starts two new phase III studies evaluating isatuximab in combination with other cancer medicines for the treatment of multiple myeloma, a rare blood cancer.

                            Arpita Dutt headshot

                            Pharma Stock Roundup: FDA Nod for NVO's Ozempic, Second Indication for Lilly's Taltz

                            FDA approval for Novo Nordisk's (NVO) type II diabetes drug, a second indication for Lilly's Taltz, and the approval of the first Herceptin biosimilar were the key highlights this week.

                              Novo Nordisk's Semaglutide Gets FDA Approval for Diabetes

                              Novo Nordisk (NVO) announced that the FDA approved semaglutide, which is a once-weekly injection approved to improve glycaemic control in adults with type II diabetes mellitus.

                                Sanofi's Toujeo Meets Key Objective in Head-to-Head Study

                                Sanofi's (SNY) head-to-head study comparing Toujeo long-acting insulin to Novo Nordisk's Tresiba long-acting insulin (insulin degludec) meets its objective.

                                  Amgen's PCSK9 Inhibitor Gets FDA Nod for Stroke Prevention

                                  Amgen (AMGN) announced FDA approval of its regulatory application seeking approval to expand Repatha's label to prevent heart attacks and strokes in patients with established cardiovascular disease.

                                    Alnylam's RNAi Candidate Gains Breakthrough Therapy Status

                                    Alnylam (ALNY) announced that the FDA has granted Breakthrough Therapy Designation for RNAi therapeutic candidate, patisiran.

                                      Alnylam Starts Rolling NDA Submission for RNAi Candidate

                                      Alnylam (ALNY) has started rolling New Drug Application to the FDA for its RNAi candidate, patisiran.

                                        Why is Alnylam's (ALNY) Stock Up More Than 200% this Year?

                                        Alnylam (ALNY) expects to achieve the profile of three marketed products by the end of 2020 and remains focused on development of its pipeline candidates.

                                          Alnylam RNAi Drug Gets Accelerated Assessment Grant From EMA

                                          Alnylam's (ALNY) RNAi candidate, patisiran, has been granted accelerated assessment by the European Medicines Agency. The company expects to file new drug application by end of 2017.

                                            Arpita Dutt headshot

                                            Novo Nordisk & 4 Other Pharma Stocks in Focus on World Diabetes Day

                                            Despite pricing pressure & competition, the diabetes market remains lucrative given the prevalence of the disease and demand for better treatments. Novo Nordisk (NVO) is a key player in this market.

                                              Impax (IPXL) Q3 Earnings & Revenues Beat Estimates, Fall Y/Y

                                              Impax (IPXL) reported dismal third-quarter results with earnings and sales coming in lower than the year-ago period. However, the company beat estimates on both counts.

                                                Arpita Dutt headshot

                                                Pharma Stock Roundup: AstraZeneca's Q3 Earnings, Roche & Merck Drugs Get FDA Nod

                                                Key highlights this week include AstraZeneca's (AZN) Q3 results and the FDA approval of the first new CMV medicine in 15 years.

                                                  Regeneron (REGN) Beats on Q3 Earnings & Sales, Shares Up

                                                  Regeneron reported impressive results in the third quarter driven by strong performance of Eylea.